Pages that link to "Q55026118"
Jump to navigation
Jump to search
The following pages link to Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. (Q55026118):
Displaying 50 items.
- Pulmonary metabolism of resveratrol: in vitro and in vivo evidence (Q24633218) (← links)
- Molecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity (Q27678202) (← links)
- Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments (Q28079705) (← links)
- Inherited disorders of bilirubin metabolism (Q28217356) (← links)
- Irinotecan-induced mucositis is associated with changes in intestinal mucins (Q28577295) (← links)
- Nuclear scintigraphic assessment of intestinal dysfunction after combined treatment with 9-amino-20(S)-camptothecin (9-AC) and irradiation (Q30305781) (← links)
- High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes (Q31002893) (← links)
- Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein (Q33267448) (← links)
- Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events (Q34391234) (← links)
- Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. (Q34512245) (← links)
- The impact of pharmacogenomics on gastrointestinal cancer therapy (Q34837030) (← links)
- Understanding and modulating mammalian-microbial communication for improved human health (Q35026463) (← links)
- Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (Q35051651) (← links)
- Pharmacogenomics: road to anticancer therapeutics nirvana? (Q35551155) (← links)
- Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo (Q36051757) (← links)
- Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. (Q36384554) (← links)
- Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection (Q36890678) (← links)
- Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. (Q37187386) (← links)
- Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38. (Q37224592) (← links)
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes (Q37378223) (← links)
- UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer (Q37402459) (← links)
- Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study (Q37441604) (← links)
- Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. (Q37697523) (← links)
- Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme (Q38734048) (← links)
- A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. (Q38781452) (← links)
- Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. (Q38945299) (← links)
- A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan (Q39139284) (← links)
- Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil (Q40024970) (← links)
- Irinotecan-induced muscle twitching from a possible drug interaction: A case report (Q40107303) (← links)
- Experimental chemotherapeutic agents for the treatment of colorectal carcinoma (Q40886133) (← links)
- Irinotecan (CPT-11): a brief overview (Q41205252) (← links)
- Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators. (Q41231401) (← links)
- Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat. (Q42180635) (← links)
- Irinotecan: a new antineoplastic agent for the management of colorectal cancer (Q42689180) (← links)
- Current perspectives on camptothecins in cancer treatment (Q42715927) (← links)
- In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats (Q43137579) (← links)
- Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. (Q43274557) (← links)
- Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients (Q43342861) (← links)
- Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients (Q44010193) (← links)
- Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. (Q44545189) (← links)
- Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats (Q44908306) (← links)
- Circadian rhythm of irinotecan tolerability in mice (Q45095461) (← links)
- Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. (Q45216034) (← links)
- Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics (Q45267582) (← links)
- Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. (Q46413208) (← links)
- Irinotecan-induced colitis (Q46466616) (← links)
- Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer (Q46491656) (← links)
- Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity (Q47107453) (← links)
- Targeting p53-dependent stem cell loss for intestinal chemoprotection. (Q50045903) (← links)
- Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon. (Q51532762) (← links)